Badrinath Konety

President, Allina Health Cancer Institute, Minneapolis and Chief Academic Officer for Allina Health. He is a Professor in the department of Urology at Rush Medical College and an Adjunct Professor of Urology at the University of Minnesota. He has recently served as The Henry P. Russe, MD, Dean of Rush University Medical College and Senior Vice President for Clinical Affairs, Rush University System for Health.

Dr. Konety was previously the Associate Dean for Innovation and Director of the Institute for Prostate and Urologic Cancers at the University of Minnesota Medical School. A distinguished professor, Dr. Konety also held the Dougherty Family Chair in Uro-Oncology. He had multiple leadership positions during his tenure at the University of Minnesota. He was Chair of the Department of Urology for more than a decade, Associate Director for Clinical Affairs at the Masonic Cancer Center and Chair of the Oncology Service Line Steering committee and also served as Chair of the Finance Committee, the Chief Executive Officer University of Minnesota Physicians and Chief Clinical Officer for MHealth Fairview .

Dr. Konety completed his residency, MBA and American Foundation for Urologic Disease Research Scholar fellowship at the University of Pittsburgh. He completed his urologic oncology fellowship at Memorial Sloan Kettering Cancer Center.
An accomplished clinician, researcher and scholar, Dr. Konety has authored or co-authored over 350 peer reviewed publications, numerous book chapters and edited two books. He has been and is principal or co-investigator on grants funded through the Department of Defense, National Institutes of Health, American Geriatrics Society, and Center for Disease Control.
Dr. Konety’s research work has focused on both basic science and outcomes/health services research. He has worked on developing new strategies for gene therapy using Ad5PSA and Ad5Trail for advanced prostate cancer with studies being translated from the lab to phase I clinical trials. He has also been involved in preclinical studies of novel chemotherapeutic agents (lupeol) for the prevention as well as inhibition of prostate cancer growth. He continues to work with collaborators on new markers for aggressive prostate cancer such as ROBO1 and S100A4. He has also been involved in developing new markers for bladder cancer. He has also led projects that focus on outcomes, cost effectiveness and quality of life in patients with bladder and prostate cancer. He has been the co lead and co-founder of CHAAMPS which is a national center conducting research on African American Men’s Health. He is also a collaborative investigator on RESTORE, a series of NIH funded studies on prostate cancer in sexual minority men.
Dr. Konety is an active member of numerous professional medical societies including the American Urological Association, the American College of Surgeons, Societe Internationale D’Urologie (SIU) and the American Association of Genitourinary Surgeons. He is the former President of the SIU, the Society of Academic Urology and the Minnesota Urologic Society. He has been the Associate Editor of the Journal of Urology. He is also a member of several other editorial boards and the executive leadership of several societies. He has received the Jahnigen Career Development Scholar Award (American Geriatric Society), the Ferdinand Valentine fellowship (New York Academy of Medicine) the David Utz award (Minnesota Urologic Society) and the Felix Guyon Medal (SIU). He was also recognized by election as a Fellow of the Royal College of Physicians and Surgeons of Glasgow. He has trained and mentored scores of students, residents and fellows.